OncoMatch/Clinical Trials/NCT06308913

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Is NCT06308913 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including INCB081776 and Pembrolizumab for head and neck squamous cell carcinoma.

Early Phase 1RecruitingUniversity of Wisconsin, MadisonNCT06308913Data as of May 2026

Treatment: INCB081776 · Pembrolizumab — This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12 participants will be enrolled and can expect to be on study for up to 12 months.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Metastatic disease required

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

UW Carbone Cancer Center · Madison, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify